Champer Miriam, Miller Devin, Kuo Dennis Yi-Shin
Department of Obstetrics & Gynecology and Women's Health, Albert Einstein College of Medicine, Montefiore Medical Center, United States.
Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Women's Health, Albert Einstein College of Medicine, Montefiore Medical Center, United States.
Gynecol Oncol Rep. 2019 Jan 31;28:26-28. doi: 10.1016/j.gore.2019.01.007. eCollection 2019 May.
Low-grade serous ovarian cancer represents a minority of ovarian cancers and has distinctive features from high grade epithelial ovarian cancer. While less aggressive, in advanced stage they can be poorly chemo-responsive and incur a treatment challenge. Next generation sequencing of tumors has allowed for the potential for targeted therapy in cancer treatment, which can allow for avoidance of traditional cytotoxic chemotherapy. We present a case of a 56 year old female with advanced recurrent low grade serous ovarian cancer found to have NRAS mutation who underwent targeted therapy with trametinib with immediate and sustained disease response. We review the response and toxicity experienced by the patient, as well as treatment for her toxicity.
低级别浆液性卵巢癌占卵巢癌的少数，与高级别上皮性卵巢癌具有不同特征。虽然其侵袭性较低，但在晚期可能对化疗反应不佳，带来治疗挑战。肿瘤的二代测序为癌症治疗中的靶向治疗提供了可能性，从而可以避免传统的细胞毒性化疗。我们报告一例56岁患有晚期复发性低级别浆液性卵巢癌的女性病例，该患者被发现存在NRAS突变，接受了曲美替尼靶向治疗，疾病立即出现持续缓解。我们回顾了患者的反应和毒性反应，以及针对其毒性的治疗情况。
